Celera formally separates from Applied Biosystems' owner for Invitrogen's $7b buy

Mervyn Jacobson, executive chairman of biotech firm Genetic Technologies (ASX:GTG, Nasdaq:GENE), says his company is poised to launch an extensive international search for license partners for its far-reaching non-coding DNA patents.

A major court victory against US firm Applera will put Genetic Technologies (ASX:GTG) in a leadership position in Australian biotechnology, the firm's CEO has predicted.

An elated Dr Mervyn Jacobson, CEO of Genetic Technologies (ASX:GTG, NASDAQ:GENE), flew back to Melbourne from San Francisco this morning after slaying his company's most reluctant dragon, giant US rival Applera.

Two deadlines have come and gone, and a third expires today for Melbourne gene-testing company Genetic Technologies (ASX:GTG; NASDAQ:GENE) and US firm Applera, who were due to announce a resolution of their licensing dispute in California today.

Melbourne gene-testing company Genetic Technologies (ASX:GTG), currently engaged in a protracted court case with giant US rival Applera over licensing and royalties for GTG's controversial non-coding DNA patents, has a potential rival in its own backyard.

Melbourne gene-test company Genetic Technologies (ASX: GTG; NASDAQ: GENE) US rival Applera Technologies have sought additional time from the US District Court of Northern California to resolve the long-running licensing dispute between the companies.

Melbourne-based gene testing company Genetic Technologies (ASX:GTG, NASDAQ:GENE) appears to be nearing settlement of its long-running court case against US rival Applera Corp over Applera's refusal to take a licence to use GTG's patents on the use of so-called 'junk' DNA markers for gene testing.

Mutual fatigue, and the peculiar challenges involved in negotiating with New Zealand's research and health-service agencies, were behind the mediated settlement of the Auckland District Health Board's dispute with Melbourne biotech Genetic Technologies (ASX:GTG) over licensing fees for GTG's non-coding DNA gene testing and mapping technology in NZ.

Clinical Cell Culture (C3, ASX:CCE) will launch CellSpray XP commercially in Europe next week at a meeting in Germany. Following the launch CellSpray XP will be available for sale in those European countries where it has regulatory approval - Austria, Denmark, Germany, Italy, The Netherlands, Switzerland and the UK.

Melbourne gene-testing company Genetic Technologies (ASX:GTG, US OTC:GNTLY) has still not resolved its patent-infringement dispute with US-based Applera Corporation, despite a second round of mediation.